Blood Cancer Journal - Table of Contents alert Volume 6 November 2016

If you are unable to see the message below, click here to view.

Advertisement Enhanced solutions for analysis of ccfDNA Detect potential new cancer driver variants at a level of 1% and less. Learn more here TABLE OF CONTENTS Volume 6, November 2016 In this issue Editorial Original Articles Letters to the Editor Advertisement Oncogenesis is an online-only, open access journal exploring the molecular basis of cancer and related phenomena. The journal seeks to promote diverse and integrated areas of molecular biology, cell biology, oncology, and genetics. Explore the benefits of submitting your next research article. Sign up for e-alerts Web feed Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders. Explore the benefits of submitting your next research article. Editorial Top Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward V Prasad and S V Rajkumar Blood Cancer J 2016 6: e489; 10.1038/bcj.2016.101 Full Text Original Articles Top Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients V De Stefano, A M Vannucchi, M Ruggeri, F Cervantes, A Alvarez-Larrán, A Iurlo, M L Randi, L Pieri, E Rossi, P Guglielmelli, S Betti, E Elli, M C Finazzi, G Finazzi, E Zetterberg, N Vianelli, G Gaidano, I Nichele, D Cattaneo, M Palova, M H Ellis, E Cacciola, A Tieghi, J C Hernandez-Boluda, E Pungolino, G Specchia, D Rapezzi, A Forcina, C Musolino, A Carobbio, M Griesshammer and T Barbui Blood Cancer J 2016 6: e493; 10.1038/bcj.2016.103 Abstract | Full Text Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells A Paulus, S Akhtar, T R Caulfield, K Samuel, H Yousaf, Y Bashir, S M Paulus, D Tran, R Hudec, D Cogen, J Jiang, B Edenfield, A Novak, S M Ansell, T Witzig, P Martin, M Coleman, V Roy, S Ailawadhi, K Chitta, S Linder and A Chanan-Khan Blood Cancer J 2016 6: e492; 10.1038/bcj.2016.93 Abstract | Full Text Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia V S Tompkins, R Sompallae, T R Rosean, S Walsh, M Acevedo, A L Kovalchuk, S-S Han, X Jing, C Holman, J E Rehg, S Herms, J S Sunderland, H C Morse and S Janz Blood Cancer J 2016 6: e488; 10.1038/bcj.2016.95 Abstract | Full Text Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients C da Cunha-Bang, J Simonsen, K Rostgaard, C Geisler, H Hjalgrim and C U Niemann Blood Cancer J 2016 6: e499; 10.1038/bcj.2016.105 Abstract | Full Text Letters to the Editor Top Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment S Betrian, L Ysebaert, K H Heider, J P Delord, J J Fournié and A Quillet-Mary Blood Cancer J 2016 6: e496; 10.1038/bcj.2016.106 Full Text Kinase-associated gene mutation pattern and clinical relevance in 205 patients with core binding factor leukemias Y-S Chen, P-P Wang, Y Hu, Y-M Zhu, B Chen, J-Y Huang, J-M Li, X-Q Weng, Y Yu and Y Shen Blood Cancer J 2016 6: e494; 10.1038/bcj.2016.107 Full Text High prevalence of viral hepatitis in a series of splenic marginal zone lymphomas from Romania B Fetica, B Pop, M L Blaga, A Fulop, D Dima, M T Zdrenghea, C I Vlad, A S Bojan, P Achimas-Cadariu, C I Lisencu, A Irimie and D D Weisenburger Blood Cancer J 2016 6: e498; 10.1038/bcj.2016.102 Abstract | Full Text Measurement of β-isomerized C-terminal telopeptide of type I collagen in patients with POEMS syndrome: diagnostic, prognostic, and follow-up utilities X Huang, C Zhang, C Wang, Q Cai, X Cao, H Cai, L Zhang, J Feng, D Zhou and J Li Blood Cancer J 2016 6: e495; 10.1038/bcj.2016.109 Abstract | Full Text In vivo magnetic resonance imaging of a mouse model of myelofibrosis S Matsuura, S Patterson, H Lucero, O Leiva, A K Grant, V L M Herrera and K Ravid Blood Cancer J 2016 6: e497; 10.1038/bcj.2016.97 Full Text Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study F Pauly, K Fjordén, S Leppä, H Holte, M Björkholm, Ø Fluge, L Møller Pedersen, M Eriksson, A Isinger-Ekstrand, C A K Borrebaeck, M Jerkeman and C Wingren Blood Cancer J 2016 6: e501; 10.1038/bcj.2016.113 Full Text Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma E Spanoudakis, M Papoutselis, E Terpos, M A Dimopoulos, C Tsatalas, D Margaritis, A Rahemtulla, I Kotsianidis and A Karadimitris Blood Cancer J 2016 6: e500; 10.1038/bcj.2016.108 Full Text Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia W Wang, Z Chen, Z Hu, C C Yin, S Li, S Bai, C E Bueso-Ramos, L J Medeiros and S Hu Blood Cancer J 2016 6: e490; 10.1038/bcj.2016.96 Full Text High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression Blood Cancer J 2016 6: e491; 10.1038/bcj.2016.99 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.